Leshem B, Tsuberi B Z, Lebendiker Z, Anafi-Ayalon M, Shalit M, Weiss L, Slavin S, Kedar E
Transplantation. 1987 Jun;43(6):814-7.
Graft-versus-host disease (GVHD), a serious complication of allogeneic bone marrow transplantation (BMT), can be prevented by in vitro depletion of T cells from the bone marrow (BM) prior to transplantation. The purpose of this study was to assess the role of BMT cells in the reconstitution of various immune functions following BMT across minor histocompatibility barriers. Lethally irradiated CBA/J (H-2k) mice were grafted with either 10(7) unseparated or T-cell-depleted BM cells from B10.BR (H-2k, minor-histoincompatible) mice. Blood counts, BM colonies in agar, and various immune functions of spleen cells from the recipient mice were tested 2-12 weeks post-BMT and compared with those of normal donors. The following observations were made: (A) Peripheral blood lymphocyte counts decreased to 30% of normal 2 weeks post-BMT with almost normal recovery at 8 weeks. (B) The percentage of Thy1.2+ splenocytes reached normal levels at 8 weeks post-BMT. (C) The number of BM colonies (GM-CFU) was reduced to 10% at 2 weeks and fully recovered at 12 weeks. (D) Proliferative response to the B-cell mitogen LPS was fully reconstituted after 4 weeks; however, anti-SRBC PFC (following Mishell-Dutton cultures) was restored 50% at 8-12 weeks. (E) Reconstitution of T cell functions including proliferative responses to concanavalin A, phytohemagglutinin, and allogeneic leukocytes, and allocytotoxicity, did not exceed 50% even 12 weeks post-BMT. Overall, depletion of T cells from donor BM allografts incompatible at minor histocompatibility loci, did not seem to significantly alter the rate of immunohematopoietic reconstitution in the lethally irradiated BM recipients.
移植物抗宿主病(GVHD)是同种异体骨髓移植(BMT)的一种严重并发症,可通过在移植前体外去除骨髓(BM)中的T细胞来预防。本研究的目的是评估BMT细胞在跨越次要组织相容性屏障进行BMT后各种免疫功能重建中的作用。对经致死剂量照射的CBA/J(H-2k)小鼠移植来自B10.BR(H-2k,次要组织不相容)小鼠的10(7)个未分离或T细胞去除的BM细胞。在BMT后2 - 12周检测受体小鼠的血细胞计数、琼脂中的BM集落以及脾细胞的各种免疫功能,并与正常供体的进行比较。得出以下观察结果:(A)BMT后2周外周血淋巴细胞计数降至正常的30%,8周时几乎恢复正常。(B)BMT后8周Thy1.2+脾细胞百分比达到正常水平。(C)BM集落(GM-CFU)数量在2周时降至10%,12周时完全恢复。(D)对B细胞有丝分裂原LPS的增殖反应在4周后完全重建;然而,抗SRBC PFC(在Mishell-Dutton培养后)在8 - 12周时恢复50%。(E)T细胞功能的重建,包括对刀豆蛋白A、植物血凝素和同种异体白细胞的增殖反应以及同种细胞毒性,即使在BMT后12周也未超过50%。总体而言,从次要组织相容性位点不相容的供体BM移植物中去除T细胞,似乎并未显著改变经致死剂量照射的BM受体中免疫造血重建的速率。